MDMA, Or Ecstasy, Shows Promise As A PTSD Treatment

The first time Lori Tipton tried MDMA, she was skeptical it would make a difference.

“I really was, at the beginning, very nervous,” Tipton said.

MDMA is the main ingredient in the club drug known as ecstasy or molly. But Tipton wasn’t taking pills sold on the street to get high. She was trying to treat her post-traumatic stress disorder by participating in a clinical trial.

With cancer risk timeline, middle-aged women recognize need for cervix screening

(Reuters Health) – When middle-aged women realize their cervical cancer risk from HPV lasts decades, more of them decide to get screened for this cancer than when they only know HPV has a role in cancer, without an explicit timeline, a small study found.

Human papillomavirus can cause cervical cancer up to 30 years after infection. Older women may think their sexual activity levels today don’t put them at risk – so uncoupling their risk perception from their current sex lives could encourage middle-aged women to understand they still need cervical cancer screening, the study authors write in the journal Sexually Transmitted Infections.

Fitbit wins deal for 1 million new users in Singapore health plan

FILE PHOTO: Visitors walk past an advertising billboard for Fitbit Ionic watches at the IFA Electronics Show in Berlin, Germany, September 1, 2017. REUTERS/Fabrizio Bensch

(Reuters) – Fitbit Inc said on Wednesday it won a contract with the Singapore government to provide fitness trackers and services to up to one million of the country’s citizens as part of a health initiative that begins in October.

The deal, which involves the company supplying its trackers free of charge but on the condition that users will spend 10 Singapore dollars ($7.23) per month for a year.

Teva launches generic version of EpiPen for young children

(Reuters) – Teva Pharmaceutical Industries Ltd on Tuesday made its generic version of Mylan’s EpiPen for young children available in most retail pharmacies at $300 for a 2-pack.

EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. REUTERS/Jim Bourg/File Photo

U.S.-listed shares of the Israel-based company rose 4.9% to $7 in afternoon trading.

Teva, the world’s largest generic drugmaker, is already selling the product for adults, after getting U.S. approval for its copy of EpiPen last August, following several years of delay.

Drugmakers Endo, Allergan agree to $15 million in settlements in major opioid case

(Reuters) – Endo International Plc (ENDP.O) and Allergan Plc (AGN.N) have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

FILE PHOTO: Bottles of several opioid based medication at a pharmacy in Portsmouth, Ohio, June 21, 2017. REUTERS/Bryan Woolston/File Photo

The tentative deals disclosed on Tuesday came ahead of the first trial to result from 2,000 lawsuits pending in federal court in Cleveland largely by local governments seeking to hold drug companies responsible for the deadly epidemic.

DIY Tech Gives People More Freedom In Managing Diabetes

When Sam Mazaheri was 9, he was diagnosed with Type 1 diabetes. That means Sam’s body makes little or no insulin, a hormone that turns food into energy.

“All of a sudden I had to manage everything he was going to take, including the insulin,” said Sam’s mom, Nasim Mazaheri.

It was frightening, she said, and it felt like bringing home a newborn all over again.

“If I give him too much, it can actually kill him, or if I don’t give him enough, it will eventually kill him.”

FDA approves Nabriva’s antibiotic for pneumonia

2019 (Reuters) – The U.S. Food and Drug Administration said on Monday that it had approved Nabriva Therapeutics Plc’s antibiotic Xenleta for treating patients with community-acquired pneumonia.

FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, 2009. REUTERS/Jason Reed/File Photo

The drug, also called lefamulin, works by interfering with the bacteria’s ability to replicate and has been approved in both injectable (IV) and oral forms. (

The drug is also Nabriva’s first to be approved by the FDA and is expected to be launched in mid-September.

Who is next in big pharma’s merger spree?

(Reuters) – Consolidation in the U.S. healthcare industry, which has already witnessed a string of multi-billion dollar deals, is expected to remain a major theme for the rest of 2019.

FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder/File Photo

Bristol-Myers Squibb’s $74 billion acquisition of Celgene set the M&A ball rolling in January, and was followed by AbbVie Inc’s $63 billion bid for troubled smaller rival Allergan Plc.

Regulators are pressuring companies to cut drug costs and takeovers have become the preferred method of combating looming patent expiries on some of the top-selling medicines they have relied upon in recent years.

CDC investigates lung illnesses linked to e-cigarette use

FILE PHOTO: A man vapes outside an office block in Manchester, Britain, February 6, 2019. REUTERS/Phil Noble/File Photo

NEW YORK (Reuters) – The Centers for Disease Control and Prevention is investigating a “cluster” of lung illnesses linked to e-cigarette use after such cases were reported in 14 states.

The CDC is working with health departments in Wisconsin, Illinois, California, Indiana and Minnesota on the investigation. Since June 28, states have reported 94 possible cases of severe lung illness tied to vaping, with 30 occurring in Wisconsin, according to a CDC statement on Saturday.

Novartis executive sold shares before drug data manipulation made public

VIENNA (Reuters) – An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated.

FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo

Novartis announced the stock sale by an executive member of the board of directors or a member of the executive committee in a Swiss stock exchange filing dated July 19. The sale was first reported by Swiss newspaper SonntagsZeitung on Sunday.